Page last updated: 2024-12-11
rhodopin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
rhodopin: RN given for (all-trans)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
rhodopin : A carotenol having the structure of 1,2-dihydro-psi,psi-carotene with a hydroxy function at C-1. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5365880 |
| CHEBI ID | 35331 |
| SCHEMBL ID | 116152 |
| MeSH ID | M0292234 |
Synonyms (28)
| Synonym |
|---|
| rhodopin/ oh-lycopene |
| LMPR01070114 |
| rhodopin |
| 1-hydroxylycopene |
| 1,2-dihydro-1-hydroxy-psi,psi-carotene |
| 1,2-dihydro-psi,psi-caroten-1-ol |
| 1-hydroxy-1,2-dihydrolycopene |
| (6e,8e,10e,12e,14e,16e,18e,20e,22e,24e,26e)-2,6,10,14,19,23,27,31-octamethyldotriaconta-6,8,10,12,14,16,18,20,22,24,26,30-dodecaen-2-ol |
| C19795 |
| psi,psi-carotene, 1,2-dihydro-1-hydroxy- |
| unii-9eyb433rxu |
| 9eyb433rxu , |
| CHEBI:35331 |
| 1,2-dihydro-1-hydroxylycopene |
| all-trans-2,6,10,14,19,23,27,31-octamethyldotriaconta-6,8,10,12,14,16,18,20,22,24,26,30-dodecaen-2-ol |
| 105-92-0 |
| IRM , |
| rhodopin [mi] |
| 1,2-dihydro-1-hydroxy-.psi.,.psi.-carotene |
| lycopene, 1,2-dihydro-1-hydroxy-, all-trans- |
| rhodopin, all-trans- |
| SCHEMBL116152 |
| .psi.,.psi.-carotene, 1,2-dihydro-1-hydroxy- |
| CNYVJTJLUKKCGM-RGGGOQHISA-N |
| lycopene, 1,2-dihydro-1-hydroxy- |
| Q15424779 |
| DTXSID201019006 |
| ze0 , |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (2)
| Class | Description |
|---|---|
| carotenol | |
| tertiary alcohol | A tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Pathways (3)
| Pathway | Proteins | Compounds |
|---|---|---|
| flexixanthin biosynthesis | 2 | 8 |
| spirilloxanthin and 2,2'-diketo-spirilloxanthin biosynthesis | 5 | 15 |
| myxol-2' fucoside biosynthesis | 4 | 12 |
Research
Studies (14)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 27.31
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.31) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||